Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 5/20 | 0.50 |
| ▸ | CES2 | O00748 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9743657 | 0.78 | GSK3B (0.52) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL543877 | 0.78 | CES1 (0.55) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL1165410 | 0.76 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL10443502 | 0.76 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL611693 | 0.76 | CES1 (0.52) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL10764490 | 0.75 | CES1 (0.46) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL15713087 | 0.74 | CES1 (0.50) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL14040704 | 0.74 | CES1 (0.57) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL11645892 | 0.74 | CES1 (0.50) | CES1CES2TSHRALDH1A1DAO | |
| SCHEMBL125975 | 0.74 | CES1 (0.50) | CES1CES2TSHRALDH1A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001041763-A1 | TREATMENT OF ADDICTION DISORDERS | UNIVERSITY OF CINCINNATI (US) | 2001-06-14 | — | — | WO | claimed |
| EP-0088729-B1 | USE OF METAL COMPLEXES OF HYDRAZONES AS PIGMENTS | CIBA-GEIGY AG (CH) | 1987-07-29 | — | — | EP | claimed |
| US-4612014-A | Use of metal complexes of hydrazones as pigments | CIBA-GEIGY CORPORATION (US) | 1986-09-16 | — | — | US | claimed |
| EP-0088729-A1 | Use of metal complexes of hydrazones as pigments | CIBA-GEIGY AG (CH) | 1983-09-14 | — | — | EP | claimed |
| US-4260540-A | SPIN DYEING POLYACRYLONITRILE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-07 | — | — | US | claimed |
| US-4225489-A | Heterocyclic azo dyes and pigments containing 4-quinazolinone moieties | BAYER AKTIENGESELLSCHAFT (DE) | 1980-09-30 | — | — | US | claimed |
| US-4042591-A | PIGMENTS, DISPERSE DYES | SANDOZ LTD. (CH) | 1977-08-16 | — | — | US | claimed |
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20080089859-A1 | ADMINISTRATION OF SLEEP RESTORATIVE AGENTS | HOLMAN ANDREW | 2008-04-17 | — | — | US | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| EP-0183191-A1 | Thienylthiazole compounds | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1986-06-04 | — | — | EP | disclosed |
| US-4410530-A | CARDIO-SELECTIVE B-RECEPTOR BLOCKING AGENTS AND STIMULANTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| EP-0088729-A1 | Use of metal complexes of hydrazones as pigments | CIBA-GEIGY AG (CH) | 1983-09-14 | — | — | EP | disclosed |
| US-4195090-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4115575-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-4052371-A | AZO PIGMENT OR DYE HAVING A NAPHTHYL-QUINAZALONE COUPLING COMPONENT | BASF AKTIENGESELLSCHAFT (DT) | 1977-10-04 | — | — | US | disclosed |
| US-4042591-A | PIGMENTS, DISPERSE DYES | SANDOZ LTD. (CH) | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | CES1 256/4885CES2 829/4885TSHR 4805/4885 |
| US-20080089859-A1 | ADMINISTRATION OF SLEEP RESTORATIVE AGENTS | GAP43, PER2, PSAP | CES1 2859/4885CES2 233/4885TSHR 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.